Prof Christine E Seidman (Brigham and Women's Hospital, MA, US) discusses actin-myosin modulation in hypertropic and dilated cardiomyopathy.
1. What is Mavacampten, what makes it a unique agent and what does it aim to address in HCM?
2. What data has been reported on the product to date?
3. What is planned in terms of the larger clinical trial program?
4. Can you describe the EXPLORER and MAVERICK study designs?
Filmed on site at ESC 2019 by Radcliffe Cardiology.
Videography: Mike Knight & Tom Green
Interviewer: Mirjam Boros